By New Statesman - 03 May 11:52
Bristol-Myers Squibb has received a Food and Drugs Agency (FDA) complete response letter about the b
By New Statesman - 30 April 15:37
Drug's first-quarter sales up nearly a third on the same period last year, generating $154 million.
By Jennifer Thompson - 28 April 17:38
Swine flu vaccine helps boost pharmaceutical and healthcare company’s profits by 16 per cent in Q1.
By Staff blogger - 28 April 12:33
Company to pay $520m.
By New Statesman - 27 April 12:46
Russian operator hopes to simplify its overall network operations model.
By New Statesman - 27 April 12:42
The software will enhance quality in conjunction with virtual autopsies.
By New Statesman - 27 April 12:28
Company reaches agreement with not-for-profit Medicines for Malaria Venture (MMV)
By New Statesman - 27 April 12:24
Biotech firm reports revenues of EUR61.68m for the full year ended December 31, 2009,
By New Statesman - 26 April 13:40
New initiative to address safety problems associated with external infusion pumps.
By New Statesman - 26 April 13:31
Co-promotion agreement for new drug
By New Statesman - 26 April 13:24
Biotage to acquire shares for 16m Swedish Kronor
By New Statesman - 22 April 12:26
The health care company made the acquisition to strengthen its presence in immunology and oncology.
By New Statesman - 22 April 12:20
The company has achieved a milestone under its collaboration agreement with Bayer Schering Pharma.
By New Statesman - 21 April 12:35
However earnings of the pharmaceuticals company were hit by US healthcare reform.
By New Statesman - 21 April 12:29
$9.5m deal will see Genentech responsible for research.
By New Statesman - 20 April 12:34
Alexander Wessels to become president and CEO of DSM Pharmaceutical Products.
By New Statesman - 19 April 12:57
The healthcare firm's first quarter sales are up CHF12.2bn (Swiss Francs).
By New Statesman - 19 April 12:53
The company is to acquire the provider of data management solutions for $17 per share in cash.
By New Statesman - 16 April 12:33
Peter Downing has been selected as North East Territory Manager for Ultrasound.
By New Statesman - 16 April 12:29
Stemgent will make reagents discovered or developed by Pfizer available to the global research commu
By New Statesman - 15 April 13:36
Robert Dougall, a former director of marketing at a Johnson & Johnson subsidiary, has been jailed fo
By New Statesman - 12 April 12:07
The pharmaceutical companies have agreed to identify and select up to five compounds for generic dev
By New Statesman - 09 April 12:15
Pharmaceutical firm gets marketing authorisation for Ribavirin 200mg film-coated tablets
By New Statesman - 08 April 13:24
Sanofi-aventis and CureDM have entered into a global licence agreement on a new human peptide which
By New Statesman - 08 April 13:18
The investor has pumped funds into the pharmaceutical company for a generic drug manufacturing facil
By New Statesman - 07 April 13:04
Research collaboration will develop individualised cancer treatment decisions.
By New Statesman - 06 April 14:35
The company has entered into an exclusive partnership with Therabel group, landing it €48.5m.
By New Statesman - 06 April 14:24
Companies come together to create therapeutics for the treatment of autoimmune and inflammatory diso
By New Statesman - 05 April 12:58
AtCor Medical, a developer and marketer of the SphygmoCor system has signed a $955,000 agreement wit
By New Statesman - 05 April 12:55
Eli Lilly and Company has received a positive Final Appraisal Determination (FAD) for chemotherapy A